CRC 03
Alternative Names: CRC-03; OVIS™ BCMA CAR-T - CurocellLatest Information Update: 11 Dec 2023
At a glance
- Originator Curocell
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical T-cell lymphoma
Most Recent Events
- 11 Dec 2023 Preclinical trials in T-cell lymphoma in South Korea (Parenteral), prior to December 2023 (Curocell pipeline, December 2023)
- 26 Feb 2021 CRC 03 is available for licensing as of 26 Feb 2021. https://curocellbtx.com/en/
- 01 Feb 2021 Early research in Multiple myeloma in South Korea (Parenteral) before February 2021 (Curocell pipeline, February 2021)